COVID-19 vaccine AZD1222 showed robust immune responses in all participants in Phase I/II trial
20 July 2020 14:40 BST COVID-19 vaccine AZD1222 showed robustimmune responses in all participants in Phase I/II trial Interim data showed strong antibody and T-cell responses Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-CoV-2 virus in all evaluated participants. COV001 is a blinded, multi-centre, randomised controlled Phase I/II trial with 1,077 healthy adult participants, aged 18-55 years. It assessed a single dose of AZD1222 against a comparator